Ophthalmology
The Department of Ophthalmology at Knappschaft Kliniken Saar GmbH concentrates on cutting‑edge research in eye diseases, with a strong emphasis on age‑related macular degeneration, glaucoma, and retinal vascular conditions. Ongoing studies seek to enhance visual acuity by evaluating new drug delivery platforms, gene‑based approaches, and complement‑targeted therapies.
- Long‑acting anti‑VEGF agents for neovascular AMD
- Port Delivery System delivering sustained ranibizumab
- Gene therapy (RGX‑314) for neovascular macular disease
- Complement component inhibition for geographic atrophy
- Intraocular timolol‑releasing implants for primary open‑angle glaucoma
- Treatments for choroidal neovascularization secondary to pathologic myopia
The site is currently supporting 8 clinical trials with the expertise of 6 investigators, contributing valuable data from Sulzbach, Germany, that may soon translate into better preservation of sight for patients affected by macular degeneration, retinal edema, and glaucoma.
